Aramark · ARMK · FY2026 Q4 · Calendar Q4 2026
Aramark Posts Record FY2026, Targets 9–10% Organic Growth in FY2027
Record FY2026 performance, strong client wins and retention, and Nexus's planned contribution underpin Aramark's maintained growth outlook. The key test is whether new-business momentum and Nexus scaling translate into durable growth and margin expansion; the supplied scorecard's slight consensus shortfalls and the execution and cash-conversion questions temper the positive operating picture.
Research this report with FN2. Free to start; review your question before sending.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about ARMK FY2026 Q4
Choose a question to continue your researchFree to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
The supplied analysis moves the story from Q3's early Nexus rollout and raised FY2026 growth outlook to FY2026's record results and a maintained FY2027 outlook. Nexus is now described as contributing to growth, with management expecting $500 million of revenue from it in FY2027. The analysis also highlights a 6.8% net-new growth rate, $1.9 billion of gross new-client wins, and enhanced shareholder returns.
Guidance delta
Management maintained its FY2027 outlook, targeting 9–10% organic revenue growth and continued margin expansion. The supplied analysis does not describe a change to that outlook.
Key takeaways
- Management characterized FY2026 as a record year for revenue, operating income and free cash flow, supported by strong net-new business and client retention.
- Aramark reported a 6.8% net-new growth rate and $1.9 billion in gross new-client wins, according to the supplied transcript analysis.
- Nexus contributed to organic growth; management expects it to add $500 million of revenue in FY2027.
- The supplied scorecard shows EPS and revenue modestly below consensus, while management maintained its FY2027 outlook.
Management priorities
- Scale Nexus across additional hyperscaler and workforce-housing locations.
- Expand collegiate, healthcare and workplace-service contracts and sustain new-business momentum.
- Use Avendra International and other supply-chain efficiencies to support operations.
- Maintain disciplined capital spending while returning capital through dividends and repurchases.
Follow ARMK with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| UBS | Buy | Buy | Maintain | Nov 11, 2026 |
| Citigroup | Buy | Buy | Maintain | Oct 12, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Aug 19, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Aug 13, 2026 |
| Stifel | Buy | Buy | Maintain | Aug 12, 2026 |
| Jefferies | Buy | Buy | Maintain | Aug 12, 2026 |
| Baird | Outperform | Outperform | Maintain | Aug 12, 2026 |
| Truist Securities | Buy | Buy | Maintain | Jul 27, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Jun 29, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jun 2, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | May 13, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | Oct 16, 2024 |
| Deutsche Bank | Buy | Hold | Upgrade | Aug 7, 2024 |
| Barclays | Underweight | Underweight | Maintain | Aug 10, 2023 |
| Bernstein | Perform | Market Perform | Maintain | Apr 19, 2023 |
| Berenberg | Buy | Hold | Upgrade | Oct 21, 2021 |
| Stifel Nicolaus | Buy | Hold | Upgrade | Aug 19, 2019 |
| Nomura | Buy | Neutral | Upgrade | Aug 19, 2019 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 10, 2018 |
| Macquarie | Outperform | Outperform | Maintain | Aug 25, 2016 |
| Bank of America | Buy | Buy | Maintain | Aug 11, 2016 |
| Sterne Agee CRT | Buy | Buy | Maintain | Mar 22, 2016 |
| Credit Agricole | Outperform | Outperform | Maintain | Oct 1, 2014 |
| Wells Fargo | Outperform | Outperform | Maintain | Jan 21, 2014 |
Named analyst price targets
Upside is calculated against the persisted current price $53.84. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Joshua Chan | $65 | $54.14 | +20.7% | Nov 11, 2026 |
| Bank of America Securities | Analyst unavailable | $69 | $54.39 | +28.2% | Oct 26, 2026 |
| RBC Capital | Analyst unavailable | $70 | $60.23 | +30.0% | Aug 19, 2026 |
| New Street | Analyst unavailable | $70 | $60.35 | +30.0% | Aug 13, 2026 |
| Jefferies | Analyst unavailable | $70 | $61.24 | +30.0% | Aug 12, 2026 |
| Deutsche Bank | Analyst unavailable | $74 | $60.46 | +37.4% | Aug 12, 2026 |
| Goldman Sachs | Analyst unavailable | $70 | $60.45 | +30.0% | Aug 12, 2026 |
| UBS | Analyst unavailable | $71 | $60.47 | +31.9% | Aug 12, 2026 |
| Robert W. Baird | Andrew Wittmann | $69 | $60.47 | +28.2% | Aug 12, 2026 |
| Morgan Stanley | Analyst unavailable | $63 | $60.47 | +17.0% | Aug 11, 2026 |
| Truist Financial | Jasper Bibb | $70 | $57.18 | +30.0% | Jul 27, 2026 |
| Robert W. Baird | Andrew Wittmann | $63 | $57 | +17.0% | Jul 24, 2026 |
| UBS | Joshua Chan | $67 | $58.3 | +24.4% | Jul 13, 2026 |
| Deutsche Bank | Analyst unavailable | $65 | $56.05 | +20.7% | Jun 29, 2026 |
| Oppenheimer | Analyst unavailable | $65 | $56.06 | +20.7% | Jun 29, 2026 |
| Oppenheimer | Ian Zaffino | $60 | $53.3 | +11.4% | Jun 11, 2026 |
| RBC Capital | Analyst unavailable | $55 | $50.87 | +2.2% | May 14, 2026 |
| Truist Financial | Jasper Bibb | $58 | $49.49 | +7.7% | May 13, 2026 |
| Deutsche Bank | Analyst unavailable | $54 | $49.34 | +0.3% | May 13, 2026 |
| Morgan Stanley | Analyst unavailable | $50 | $49.24 | -7.1% | May 13, 2026 |
| UBS | Analyst unavailable | $56 | $48.4 | +4.0% | May 13, 2026 |
| Robert W. Baird | Analyst unavailable | $58 | $48.4 | +7.7% | May 13, 2026 |
| Goldman Sachs | Analyst unavailable | $51 | $48.4 | -5.3% | May 13, 2026 |
| Truist Financial | Analyst unavailable | $50 | $39.27 | -7.1% | Feb 17, 2026 |
| UBS | Analyst unavailable | $47 | $41.32 | -12.7% | Feb 11, 2026 |
| Robert W. Baird | Analyst unavailable | $50 | $40.96 | -7.1% | Feb 11, 2026 |
| Morgan Stanley | Toni Kaplan | $45 | $40.96 | -16.4% | Feb 10, 2026 |
| Robert W. Baird | Analyst unavailable | $46 | $36.68 | -14.6% | Nov 18, 2025 |
| Stifel Nicolaus | Analyst unavailable | $44 | $36.04 | -18.3% | Nov 17, 2025 |
| UBS | Analyst unavailable | $45 | $38.4 | -16.4% | Oct 1, 2025 |
| UBS | Analyst unavailable | $46 | $39.56 | -14.6% | Aug 6, 2025 |
| Morgan Stanley | Toni Kaplan | $43 | $40.4 | -20.1% | Dec 12, 2024 |
| RBC Capital | Karl Green | $42.5 | $38.53 | -21.1% | Sep 17, 2024 |
| Truist Financial | Jasper Bibb | $42 | $37.99 | -22.0% | Sep 11, 2024 |
| Robert W. Baird | Andrew Wittmann | $38 | $34.62 | -29.4% | Aug 7, 2024 |
| Deutsche Bank | Faiza Alwy | $39 | $33.66 | -27.6% | Aug 7, 2024 |
| Oppenheimer | Ian Zaffino | $39 | $32.9 | -27.6% | Jun 12, 2024 |
| Jefferies | Stephanie Moore | $37 | $32 | -31.3% | Jun 4, 2024 |
| Truist Financial | Jasper Bibb | $37 | $31.59 | -31.3% | Mar 20, 2024 |
| Goldman Sachs | Lizzie Dove | $33 | $28.81 | -38.7% | Jan 17, 2024 |
| J.P. Morgan | Analyst unavailable | $44 | $40.89 | -18.3% | Feb 8, 2023 |
| Morgan Stanley | Analyst unavailable | $44 | $41.96 | -18.3% | Jan 4, 2023 |
| Barclays | Analyst unavailable | $36 | $41.9 | -33.1% | Dec 2, 2022 |
| Deutsche Bank | Analyst unavailable | $43 | $40.51 | -20.1% | Nov 16, 2022 |
| Morgan Stanley | Analyst unavailable | $41 | $39.94 | -23.8% | Nov 16, 2022 |
| RBC Capital | Analyst unavailable | $45 | $40.55 | -16.4% | Nov 16, 2022 |
| Morgan Stanley | Analyst unavailable | $38 | $33.1 | -29.4% | Sep 27, 2022 |
| Morgan Stanley | Analyst unavailable | $37 | $36.44 | -31.3% | Aug 10, 2022 |
| Oppenheimer | Ian Zaffino | $32.49 | $24.89 | -39.7% | Jul 21, 2021 |
Track every rating change on ARMK the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationBased in Philadelphia, Pennsylvania, Aramark, established in 1959, provides a comprehensive array of services encompassing food management, facility solutions, and uniform provision. The company serves a diverse global clientele, including educational institutions, healthcare providers, various businesses and industrial clients, sports and entertainment venues, leisure operators, and correctional facilities, both within the United States and internationally. Aramark organizes its operations into three primary divisions: U.S. Food and Support Services, International Food and Support Services, and Uniform and Career Apparel. Its extensive food-related offerings feature managed dining programs, catering solutions, food service management, and convenience retail options. This includes operating on-site restaurants, providing executive dining experiences, managing convenience stores, and offering beverage and vending services.…
Historical context
All ARMK earningsIndustrials peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| FRO Frontline Plc | FY2026 Q3 · Calendar Q4 2026 | — | +2.2% | Frontline posts record Q3 profit as spot tanker rates surge |
| WWD Woodward, Inc. | FY2026 Q4 · Calendar Q4 2026 | +11.4% | +6.9% | Woodward reports record FY2026 results and outlines growth priorities for 2027 |
| ZTO ZTO Express (Cayman) Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.9% | -0.7% | Volume and retail-parcel growth support profit gains, with guidance cautious |
| ESLT Elbit Systems Ltd. | FY2026 Q3 · Calendar Q4 2026 | +1.4% | +5.8% | Elbit’s record backlog supports raised 2027 growth outlook, with execution risks |
| ACM Aecom | FY2026 Q4 · Calendar Q4 2026 | — | +11.1% | AECOM closes FY2026 with record backlog and margin; FY2027 outlook maintained |
| TTEK Tetra Tech, Inc. | FY2026 Q4 · Calendar Q4 2026 | +4.6% | +4.8% | Tetra Tech’s FY2026 Backlog Growth Supports a Strong FY2027 Pipeline |
Latest beats and misses
Who reports nextBeat on EPS
- INTUFY2027 Q1 · November 19, 2026+18.3% EPS-6.2% move
- ROSTFY2026 Q3 · November 19, 2026+2.1% EPS-2.8% move
- ESTCFY2027 Q2 · November 19, 2026+16.2% EPS+2.0% move
- KEYSFY2026 Q4 · November 19, 2026+7.1% EPS-1.5% move
- WSMFY2026 Q3 · November 19, 20260.0% EPS-15.2% move
- WMGFY2026 Q4 · November 19, 2026+50.9% EPS-0.6% move
Missed on EPS
- NTESFY2026 Q3 · November 19, 2026-12.8% EPS-11.4% move
- FUTUFY2026 Q3 · November 19, 2026-7.8% EPS+4.8% move
- BABAFY2027 Q2 · November 19, 2026-29.2% EPS-1.3% move
- SQMFY2026 Q3 · November 17, 2026-3.0% EPS-5.5% move
- VIKFY2026 Q3 · November 17, 2026-12.6% EPS+4.4% move
- XPFY2026 Q3 · November 16, 2026-3.0% EPS-2.5% move
Get the ARMK recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-16T17:10:32.528493+00:00
- FN2 earnings calendar · 2026-11-17T01:23:14.281446+00:00
- Polygon adjusted daily market bars · 2026-11-17T05:30:49.948906+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-17T05:30:49.946185+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-17. For educational purposes only; not investment advice.